Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduning Injection for prevention of sepsis in high-risk adults with respiratory infections
ChiCTR2600132244Phase 4Not yet recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Reduning in Airways Infection (2 arms), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Proportion of participants progressing to sepsis or septic shock within 14 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Reduning
03
Conditions
Airways Infection
Beyond the preview
Go deeper on ChiCTR2600132244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132244.